#Myeloproliferative Neoplasms #Jubilant Therapeutics #JBI-802

Celebrating Advances in Hematology: JBI-802 Overview

Jubilant Therapeutics, a prominent player in the biopharmaceutical sector, has made waves with its latest announcement regarding JBI-802, a pioneering oral treatment aimed at addressing critical deficiencies in therapies for myeloproliferative neoplasms (MPNs). Scheduled for an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting from December 12 to 15, 2026, this early-stage clinical data offers a promising glimpse into the potential impact of JBI-802 on patients with essential thrombocythemia (ET) and related conditions.

The Significance of JBI-802

JBI-802 is a first-in-class oral dual inhibitor targeting lysine-specific demethylase 1 (LSD1) and histone deacetylase 6 (HDAC6), collectively known as the CoREST complex. This medication aims to address several disease-relevant mechanisms impacting MPNs, such as disrupted megakaryocyte differentiation and excessive platelet production. Given the challenges associated with conventional care for recurrent and refractory patients, JBI-802 represents a promising innovation that could herald a new era in therapeutic options for those suffering from these debilitating conditions.

Clinical Data Highlights

During the Phase 1 trial, participants who received 15 mg of JBI-802 demonstrated remarkable results. By the end of Week 3, every one of the eight patients noted a reduction in platelet counts of more than 50% or achieved normalization (with levels below 400 × 10⁹/L). Remarkably, the median response time was just 15 days, indicating both efficacy and speed in treatment response. For patients monitored over longer durations—specifically those with a follow-up of over 12 weeks—platelet normalization persisted through 33, 44, and even 46 weeks.

Moreover, favorable outcomes extended to leukocytosis, where seven of the eleven patients treated at the 15 mg dosage achieved a complete hematologic response. Notably, throughout this course, investigators reported no dose-limiting toxicities at the lower doses of 5, 7, and 15 mg, reinforcing the safety profile of JBI-802.

Upcoming Presentation Details

The oral presentation at ASH will cover extensive safety and preliminary efficacy results from this multicenter, open-label study. The presentation is expected to furnish further insights into the drug's molecular mechanisms and its broader clinical applications. Leading the discussion will be Dr. Andrew McQuillan, whose expertise will shed light on the significance of these findings within the context of the evolving landscape of MPN treatments.

In addition to this presentation, Jubilant will also be hosting a corporate event titled, "Dual LSD1/HDAC6 Inhibition with JBI-802 in Thrombocytosis-Predominant MPN Clinical Data and Emerging Perspectives," scheduled for December 14, 2026. This session will elaborate on the Phase 1 data and discuss its clinical implications for ongoing and future therapy development.

About Jubilant Therapeutics

Founded with a vision to revolutionize treatment paradigms for hematological conditions, Jubilant Therapeutics harnesses deep expertise in medicinal chemistry and translational science to advance targeted therapeutics. In addition to JBI-802, the company's innovative pipeline includes JBI-3041, a first-in-class inhibitor showing promise across various autoimmune diseases.

As the healthcare landscape undergoes continuous transformation, Jubilant Therapeutics stands at the forefront, dedicated to crafting new possibilities for patient care. Following the ASH presentations, relevant materials will be accessible on their website—showcasing the organization’s commitment to transparency and scientific discourse.

For up-to-date information, follow Jubilant Therapeutics on their official channels, including social media platforms like X and LinkedIn.